“I am proud to have had the opportunity to serve Karim and his leadership team. He is a brilliant leader who has an unparalleled ability to balance respect for people with a drive to create world-class results. He also has the very unique ability to truly transform an entire business into an engaging, competitive engine for value creation. Having worked with many leaders around the world, Karim is a true example of what a global leader should be.”
Activity
-
The Governor of Indiana, the Honorable Eric J. Holcomb, First Lady Janet Holcomb, and a distinguished group of senators and other officials visit…
The Governor of Indiana, the Honorable Eric J. Holcomb, First Lady Janet Holcomb, and a distinguished group of senators and other officials visit…
Liked by Karim Bitar
-
Had the opportunity this weekend to attend, and enjoy, my oldest daughter’s choir concert at Carroll University. It’s not something I get to do all…
Had the opportunity this weekend to attend, and enjoy, my oldest daughter’s choir concert at Carroll University. It’s not something I get to do all…
Liked by Karim Bitar
-
THIS IS A MURAL BY MY SON RAFAEL CARO IN BROAD RIPPLE INDIANAPOLIS. It contains a positive message to all artists "Within all artists is a hunger for…
THIS IS A MURAL BY MY SON RAFAEL CARO IN BROAD RIPPLE INDIANAPOLIS. It contains a positive message to all artists "Within all artists is a hunger for…
Liked by Karim Bitar
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Activities and Societies: Unilever Scholar
-
-
Activities and Societies: Dow Chemical Scholarship
Languages
-
Italian
-
-
Arabic
-
-
French
-
-
Spanish
-
-
English
-
Recommendations received
-
LinkedIn User
1 person has recommended Karim
Join now to viewMore activity by Karim
-
I was in Glasgow for a couple days this week with the Convatec team for the World Council of Enterostomal Therapists (WCET) and Association of Stoma…
I was in Glasgow for a couple days this week with the Convatec team for the World Council of Enterostomal Therapists (WCET) and Association of Stoma…
Shared by Karim Bitar
-
Tanta emozione oggi nel ricevere il titolo di “Poliziotto ad honorem” dalle mani del Capo della Polizia. E' stato bello leggere la motivazione. La…
Tanta emozione oggi nel ricevere il titolo di “Poliziotto ad honorem” dalle mani del Capo della Polizia. E' stato bello leggere la motivazione. La…
Liked by Karim Bitar
-
We hope you enjoyed last night's at-booth expert talk: Challenges in Pouching: Using an Algorithm to Save You Time and Your Patient’s Skin at the…
We hope you enjoyed last night's at-booth expert talk: Challenges in Pouching: Using an Algorithm to Save You Time and Your Patient’s Skin at the…
Liked by Karim Bitar
-
Did you miss Dr. Neal Carty and Dr. Tod Brindle's convexity talks today at WCET ASCN 2024? Don't worry, there's so much more to cover at our…
Did you miss Dr. Neal Carty and Dr. Tod Brindle's convexity talks today at WCET ASCN 2024? Don't worry, there's so much more to cover at our…
Liked by Karim Bitar
-
I returned to London this week from time in the United States. It was good to be back in New York and Washington DC with investors, partners and…
I returned to London this week from time in the United States. It was good to be back in New York and Washington DC with investors, partners and…
Shared by Karim Bitar
Other similar profiles
Explore more posts
-
Jedrzej Litwiniuk, MHA
Check out AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we’re thrilled to share these results with you! Check out the attached presentation for more details. If you’d like the full version of the deck, feel free to reach out directly to @Uwe Tigör, MD or to me #cardiology #CSAP #AUX001 #ESC #newmedication #biotech #news
-
Lorenz Mayr
More exciting news on GLP-1 agonists: At a time when you think the excitement could not be any higher, we hear even more promising news about clinical use of GLP-1 agonists. “The Times” published an article this morning (May 14) with these key messages: 1. Millions of middle-aged Britons should be routinely prescribed weight-loss injections to cut their risk of heart attacks and strokes by a fifth, according to a trial set to revolutionise medical practice. 2. The largest study ever into semaglutide, also known as Ozempic or Wegovy, found the drug cuts heart disease deaths by about 20 per cent even if people don’t lose weight. 3. The results — presented at the European Congress on Obesity in Venice — were hailed as the biggest medical breakthrough since the introduction of statins in the 1990s. A link to the publication in Nature Medicine and a link to the clinical study named SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) is attached below. Key findings are as follows: 1. The trial involved 17,604 adults over the age of 45 who had heart disease — a condition that affects 7.6 million in the UK — or had had a heart attack or stroke. All were overweight or obese, but none had diabetes. Half were given weekly semaglutide injections and the rest a placebo. 2. Over a trial period of three years and four months, the group who took semaglutide had a 20 per cent lower risk of heart attack, stroke or death from heart disease and also lost nine per cent of their body weight on average. 3. The drug delivered heart benefits regardless of how much weight people lost. Times articles: https://lnkd.in/gwHVj3P6 https://lnkd.in/gSk-HQTV Clinical results: https://lnkd.in/gvAmaBY8 https://lnkd.in/gAJEWPZF News: https://lnkd.in/gyDZ8wGN https://lnkd.in/gF_UK9W8 https://lnkd.in/gximb9S6 https://lnkd.in/gfqvZFd9 https://lnkd.in/g-pDYRJp
2 Comments -
Alexander Gray
The 2024 Pharmaceutical Innovation and Invention Index is live! We are proud to publish this year's indices: the 13th year of analysing innovation and invention in our industry. https://lnkd.in/e_b_TtCY The question, 'if you give the same molecule to two companies in phase I, would they be equally successful?' remains a defining one. The answer is clearly 'no,' so the more interesting question is 'why'?'—perhaps one of the most important questions for our industry. When we first asked ourselves that question, more than a decade ago, it followed a more soul-searching one: ‘what if we're wrong?’ A healthy question, but not one that is typical of consultancies. Understanding how companies create value from their pipelines means being open to novel and multiple approaches - we produce this Index so that we know what we’re talking about when we talk about pharmaceutical innovation. If you like, we’re ‘following the science’ rather than assuming we’re right.
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Karim Bitar
-
Karim Bitar
Chief Executive Officer
-
Karim Bitar
-
KARIM ALBITAR
Private Teacher | Mechanical Engineering, Training
-
Karim Bitar
Founder at KBAS Ottawa Inc.
25 others named Karim Bitar are on LinkedIn
See others named Karim Bitar